ABIVAX Société Anonyme (ABVX)
AI-powered earnings prediction for ABIVAX Société Anonyme (ABVX).
116.48
-2.50%
USD, 1 day ago
Company Overview
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Sector
Healthcare
Industry
Biotechnology
Website
www.abivax.comPhone
33 1 53 83 09 63
Headquarters
7-11 boulevard Haussmann
Paris, 75009
France
Full-Time Employees
69
Key Metrics
Forward P/E
-41.40
Price to Book
17.54
Beta
-0.10
Profit Margin
0.00%
Gross Margin
100.00%
Return on Equity
-135.58%
Return on Assets
-38.95%
Earnings Growth
N/A
Revenue Growth
-55.40%
Financial Health
Total Cash
$530.38M
Total Debt
$32.09M
Debt to Equity
7.05
Current Ratio
8.75
Free Cash Flow
$-118316624.00
Operating Cash Flow
$-161128992.00
Analyst Recommendations
Target Price (Mean)
$155.20
Target High
$176.00
Target Low
$131.00
Recommendation
strong_buy
Analyst Coverage
10 Analysts